On 23 August 2017, TreatSMA along with SMA Trust, SMA Support UK and MD UK signed a letter addressed to the Head of Specialised Commissioning Team at NHS England. We urged a review of the published commissioning policy for inclusion of SMA 1 patients in the Expanded Access Programme of nusinersen.
Roche shared an update on the safety of RG7916.
NHS England has published an Interim Commissioning Policy on nusinersen EAP.